GOSS (Gossamer Bio) EBIT per Share: $-0.74 (TTM As of Mar. 2026)


GOSS Gossamer Bio Inc GOSS
16 GF Score
Price $0.17
! 5 Warning Signs
View Full Analysis

What is Gossamer Bio EBIT per Share?

Gossamer Bio GOSS +3.28% 16 EBIT per Share is $-0.74 as of Mar. 2026. GuruFocus rates GOSS with a GF Score™ of 16/100. The stock has 5 warning signs investors should review. Among 1,178 Biotechnology companies, Gossamer Bio ranks better than 73.85% on this metric.

Gossamer Bio's EBIT per Share for the three months ended in Mar. 2026 was $-0.19. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.74.

During the past 3 years, the average EBIT per Share Growth Rate was 34.90% per year. During the past 5 years, the average EBIT per Share Growth Rate was 35.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Gossamer Bio's EBIT per Share or its related term are showing as below:

GOSS' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -935.9   Med: 8.2   Max: 54.9
Current: 34.9

During the past 10 years, the highest 3-Year average EBIT per Share Growth Rate of Gossamer Bio was 54.90% per year. The lowest was -935.90% per year. And the median was 8.20% per year.

GOSS's 3-Year EBIT Growth Rate is ranked better than
73.85% of 1178 companies
in the Biotechnology industry
Industry Median: 15.55 vs GOSS: 34.90

Gossamer Bio's EBIT for the three months ended in Mar. 2026 was $-43.91 Mil.

Gossamer Bio  (NAS:GOSS) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Gossamer Bio EBIT per Share Related Terms

Gossamer Bio EBIT per Share Historical Data

* Premium members only.

The historical data trend for Gossamer Bio's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gossamer Bio EBIT per Share Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.87 -2.55 -1.09 -0.20 -0.70

Gossamer Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.16 -0.20 -0.19 -0.19
GOSS
16GF Score
Gossamer Bio Inc GOSS
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gossamer Bio EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Gossamer Bio's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-159.469/228.519
=-0.70

Gossamer Bio's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-43.909/234.137
=-0.19

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $-0.74 mean?
Gossamer Bio (GOSS) has a EBIT per Share of $-0.74 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Gossamer Bio and its competitors. According to the industry distribution chart, Gossamer Bio ranks #308 out of 1178 companies in the Biotechnology industry, placing it in the top 26.1%.
Is Gossamer Bio's EBIT per Share too high?
Gossamer Bio's current EBIT per Share is $-0.74. Based on the distribution chart, Gossamer Bio ranks #308 out of 1178 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Gossamer Bio has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Gossamer Bio's EBIT per Share compare to ELTX and ACET?
According to the Biotechnology industry distribution chart, Gossamer Bio ranks #308 out of 1178 companies for EBIT per Share. This puts Gossamer Bio in the upper half of its industry. The industry median EBIT per Share is 15.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.55, based on 1,178 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Gossamer Bio and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gossamer Bio's current EBIT per Share is $-0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gossamer Bio stock overvalued right now?
Gossamer Bio (GOSS) has a current EBIT per Share of $-0.74. The current EBIT per Share is $-0.74. Gossamer Bio's overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Gossamer Bio (GOSS), the current EBIT per Share is $-0.74 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gossamer Bio Business Description

Other Exchanges 4GB:Germany
Address 3115 Merryfield Row, Suite 120, San Diego, CA, USA, 92121
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
16GF Score

Get the complete analysis for GOSS

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price